Literature DB >> 28713064

Novel risk stratification for metachronous recurrence after curative endoscopic submucosal dissection for early gastric cancer.

Hyo-Joon Yang1, Sang Gyun Kim2, Joo Hyun Lim3, Ji Min Choi3, Sooyeon Oh2, Jae Yong Park2, Seung Jun Han2, Jung Kim2, Hyunsoo Chung2, Hyun Chae Jung2.   

Abstract

BACKGROUND AND AIMS: This study stratified the risk of developing metachronous gastric cancer (MGC) after curative endoscopic submucosal dissection (ESD) of early gastric cancer (EGC) to enable customization of endoscopic surveillance for MGC.
METHODS: A total of 1115 patients who underwent curative ESD based on the expanded criteria for differentiated EGC from 2005 to 2014 at a single tertiary hospital were enrolled in this retrospective cohort study. They were followed up with annual endoscopy for a median of 50.1 months. Helicobacter pylori and histologic intestinal metaplasia (IM) were evaluated. The Kaplan-Meier method and Cox regression analysis were used for risk stratification.
RESULTS: Three risk groups were identified: group 1 comprised patients with a synchronous neoplasm; group 2 comprised male patients with corpus IM; and group 3 comprised male patients without corpus IM or female patients. The 5- and 7-year cumulative risks (95% confidence interval [CI]) for metachronous recurrence were 15.1% (95% CI, 7.7-22.5) and 26.1% (95% CI, 14.9-37.3), respectively, in group 1; 5.6% (95% CI, 3.1-8.1) and 9.3% (95% CI, 5.4-13.2), respectively, in group 2; and 3.8% (95% CI, 1.6-6.0) and 4.9% (95% CI, 2.4-7.4), respectively, in group 3 (P < .001 by log-rank test). The incidence of MGCs increased constantly even after 5 years in groups 1 and 2 but not in group 3. There was not enough evidence to show an association between H pylori eradication and metachronous recurrence in the data.
CONCLUSIONS: Meticulous annual endoscopic surveillance for MGC for more than 5 years is recommended for patients with synchronous neoplasm. Endoscopic surveillance may also be extended beyond 5 years in male patients with corpus IM.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28713064     DOI: 10.1016/j.gie.2017.07.005

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  5 in total

1.  Endoscopic Submucosal Dissection for the Treatment of Superficial Epithelial Gastric Neoplasia in a Portuguese Centre.

Authors:  Rita Seara Costa; Aníbal Ferreira; Tiago Leal; Dalila Costa; Carla Rolanda; Raquel Gonçalves
Journal:  GE Port J Gastroenterol       Date:  2018-04-11

Review 2.  Characteristics and predictors of gastric cancer after Helicobacter pylori eradication.

Authors:  Satoki Shichijo; Yoshihiro Hirata
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

Review 3.  Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer.

Authors:  Chan Hyuk Park; Dong-Hoon Yang; Jong Wook Kim; Jie-Hyun Kim; Ji Hyun Kim; Yang Won Min; Si Hyung Lee; Jung Ho Bae; Hyunsoo Chung; Kee Don Choi; Jun Chul Park; Hyuk Lee; Min-Seob Kwak; Bun Kim; Hyun Jung Lee; Hye Seung Lee; Miyoung Choi; Dong-Ah Park; Jong Yeul Lee; Jeong-Sik Byeon; Chan Guk Park; Joo Young Cho; Soo Teik Lee; Hoon Jai Chun
Journal:  Clin Endosc       Date:  2020-03-30

4.  Exploring the Link between Helicobacter pylori Eradication and Metachronous Gastric Cancer Development.

Authors:  Hyo-Joon Yang
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

5.  Clinical practice guideline for endoscopic resection of early gastrointestinal cancer.

Authors:  Chan Hyuk Park; Dong-Hoon Yang; Jong Wook Kim; Jie-Hyun Kim; Ji Hyun Kim; Yang Won Min; Si Hyung Lee; Jung Ho Bae; Hyunsoo Chung; Kee Don Choi; Jun Chul Park; Hyuk Lee; Min-Seob Kwak; Bun Kim; Hyun Jung Lee; Hye Seung Lee; Miyoung Choi; Dong-Ah Park; Jong Yeul Lee; Jeong-Sik Byeon; Chan Guk Park; Joo Young Cho; Soo Teik Lee; Hoon Jai Chun
Journal:  Intest Res       Date:  2020-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.